Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
FOSCARNET TRISODIUM HEXAHYDRATE
LINK HEALTHCARE SINGAPORE PTE LTD
J05AD01
24 mg/ml
INJECTION
FOSCARNET TRISODIUM HEXAHYDRATE 24 mg/ml
INTRAVENOUS
Prescription Only
Fresenius Kabi Austria GmbH
ACTIVE
1995-06-29
FOSCAVIR Infusion 24 mg/ml Solution for infusion COMPOSITION Solution for intravenous infusion. 1 ml contains 24 mg (80 μmol) foscarnet trisodium hexahydrate*, hydrochloride acid q.s. and water for injection q.s. The solution is sterile, clear and isotonic with a pH of 7.4. *foscanet sodium (rINN) or trisodium phosphonoformate hexahydrate or phosphonoformic acid trisodium salt hexahydrate. DESCRIPTION Antiviral and pharmacological properties Foscarnet is an antiviral agent with a broad antiviral spectrum which inhibits all known human viruses of the herpes group, herpes simplex virus type 1 and 2, human herpes virus 6, varicella zoster virus, Epstein-Barr virus and cytomegalovirus (CMV) and some retroviruses, including human immunodeficiency virus (HIV) at concentrations not affecting normal cell growth. Foscarnet also inhibits the viral DNA polymerase from hepatitis B virus. Foscarnet exerts its antiviral activity by a direct inhibition of viral specific DNA polymerase and reverse transcriptase. The mean FOSCAVIR 50% inhibition value (ID50) for more than one hundred clinical CMV isolates is approximately 270 μmol/l, while a reversible inhibition of normal cell growth was observed at about 1000 μmol/l. In several animal species foscarnet is rapidly cleared from the blood and other soft tissues after intravenous administration. The most pronounced effects noted during general toxicity studies performed with Foscavir are perturbation of some serum electrolytes, and kidney and bone changes. An observed reduction of serum electrolytes such as calcium and magnesium can be explained by the property of Foscavir to form chelate with divalent metal ions. The reduction of ionized calcium and magnesium is, most probably, the explanation to seizures/convulsions seen during and shortly aft Read the complete document
Page 1 of 10 FOSCAVIR INFUSION 24 MG/ML Solution for infusion COMPOSITION Solution for intravenous infusion. 1 ml contains 24 mg (80 μmol) foscarnet trisodium hexahydrate*, hydrochloride acid (E507) q.s. and water for injection q.s. The solution is sterile, clear and isotonic with a pH of 7.4. *foscarnet sodium (rINN) or trisodium phosphonoformate hexahydrate or phosphonoformic acid trisodium salt hexahydrate. DESCRIPTION ANTIVIRAL AND PHARMACOLOGICAL PROPERTIES Foscarnet is an antiviral agent with a broad antiviral spectrum which inhibits all known human viruses of the herpes group, herpes simplex virus type 1 and 2, human herpes virus 6, varicella zoster virus, Epstein-Barr virus and cytomegalovirus (CMV) and some retroviruses, including human immunodeficiency virus (HIV) at concentrations not affecting normal cell growth. Foscarnet also inhibits the viral DNA polymerase from hepatitis B virus. Foscarnet exerts its antiviral activity by a direct inhibition of viral specific DNA polymerase and reverse transcriptase. The mean Foscavir 50% inhibition value (IC 50 ) for more than one hundred clinical CMV isolates is approximately 270 μmol/l, while a reversible inhibition of normal cell growth was observed at about 1000 μmol/l. In several animal species foscarnet is rapidly cleared from the blood and other soft tissues after intravenous administration. The most pronounced effects noted during general toxicity studies performed with Foscavir are perturbation of some serum electrolytes, and kidney and bone changes. An observed reduction of serum electrolytes such as calcium and magnesium can be explained by the property of Foscavir to form chelate with divalent metal ions. The reduction of ionized calcium and magnesium is, most probably, the explanation to seizures/convulsions seen during and shortly after the infusion of high doses of Foscavir. This reduction may also have a bearing on heart function (e.g. ECG) although the toxicological studies performed did not disclose any such effects. The rate of infusion Read the complete document